Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity
Hayman T. Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity. JNCI Cancer Spectrum 2024, 8: pkae045. PMID: 38950525, PMCID: PMC11216723, DOI: 10.1093/jncics/pkae045.Peer-Reviewed Original ResearchBiomarkers, TumorCheckpoint Kinase 2Drug Resistance, NeoplasmGerm-Line MutationHumansPoly(ADP-ribose) Polymerase Inhibitors